This trial is evaluating whether Ipilimumab will improve 5 primary outcomes and 7 secondary outcomes in patients with Metastatic Carcinoma in the Liver. Measurement will happen over the course of Up to 29 days for groups 1 and 3, up to day 43 for group 2.
This trial requires 60 total participants across 3 different treatment groups
This trial involves 3 different treatments. Ipilimumab is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"The majority of people with cancer are treated by a team of professionals including nurses, surgeons, and oncologists. Many patients have to endure the discomfort of chemotherapy, radiotherapy, pain and other side-effects. Many more cases of cancer can be prevented by making changes to lifestyle. Tobacco smoking is a significant cause of lung cancer. Although most people have access to smoking cessation support from a nurse, a more effective and less stigmatizing support might help smokers, as well as those with cancer, manage and cope with their disease." - Anonymous Online Contributor
"Many of the following symptoms are not related to cancer itself but to the treatment or other medical conditions a person has that might mimic certain signs of cancer." - Anonymous Online Contributor
"Various genetic factors and environmental hazards appear to converge to increase the odds of developing cancer, probably as a result of multiple genomic aberrations or epigenetic alterations." - Anonymous Online Contributor
"Around 703,500 new cancer cases occur each year in the United States, including 355,600 cases of cervical cancer and 258,100 of breast cancer. The annual number of cases of colon cancer, cancer of the stomach, and cancer of the pancreas is about 70,500; of oral cancer is about 34,000. Lung cancer, kidney cancer, and brain cancer comprise about 36,500 new cases each year. A few important differences have been observed in the rates of cancer in different racial groups and between men and women." - Anonymous Online Contributor
"Treatment with systemic chemotherapy in patients with colorectal cancer is associated with significant survival. However, current trends indicate that survival in colorectal cancer will most likely remain below average levels in the near future." - Anonymous Online Contributor
"While cancer is a progressive condition, its underlying causes, like genetic alterations and environmental factors, are not entirely understood. It is therefore important to maintain awareness of cancer. Copyright © 2015 John Wiley & Sons, Ltd." - Anonymous Online Contributor
"To date, some 50 oncological diseases and conditions have been associated with ipilimumab [4], but to date, a clear pattern has not emerged. These have included primary immunologic conditions such as interstitial lung disease, autoimmune or rheumatic disease [5], autoimmune disorders [e.g., systemic lupus erythematosus and Sjögren’s syndrome] [6], connective tissue disorders [e.g." - Anonymous Online Contributor
"This is the largest study published in the literature to date in which ipilimumab is studied in a cohort that includes people older than 70 years of age. In a preliminary analysis, no significant changes were observed in rates of AEs between the 2 age cohorts. These data from the phase II study validate the safety and tolerability of ipilimumab when it is given at the highest dose in patients who are 70 years or older." - Anonymous Online Contributor
"Almost one quarter of subjects with no health problems on a general population, cohort developed cancer before the age of 60. Overall cancer incidence was 2 times higher than expected. Subjects already diagnosed with breast cancer have a considerably lower rate of developing further cancer. Thus the lifetime risk of developing cancer is higher for those with an early onset breast cancer than for those with later onset breast cancer. There was no difference on the risk between men and women, or between family members of either gender. The observed difference in cancer rates between men and women cannot be explained by their different lifetime risks." - Anonymous Online Contributor
"A new treatment method called radiation oncology (radiation, chemotherapy, or other therapies) is available for many cancer types, but even so, a full cure is still very likely not practical unless there are major advances in understanding cellular signaling in cancer. Recent advances in genetics have produced a huge new set of new tools, which could lead to a greater understanding of the signal-transduction mechanisms that control cell growth and the mechanisms by which cancer cells escape the regular cell death process known as apoptosis or programmed cell death. In particular, cancer cells have several different pathways through which they can escape this process." - Anonymous Online Contributor
"As all cancers cause death earlier than their diagnosis in most parts of the world (this may be due to people being more actively engaged in treatment and survival) the average age of diagnosis is skewed towards earlier ages in the tropics. This is unfortunate, because it means that people with cancer are diagnosed when they are most vulnerable and unable to take advantage of interventions to prevent the development of secondary cancer\n\nAs mentioned above, it is generally true in countries like India that those diagnosed with cancer receive comparatively poorly funded cancer care than those who are healthier. Therefore, in India, less developed areas are less likely to receive the care they need and thus die of illness sooner than industrialized countries." - Anonymous Online Contributor
"Recent findings showed that ipilimumab has shown effectiveness against cancer when compared to placebo. The survival was higher. The median survival was 2.3 months in the study arm compared to 3 months in the placebo arm. The most adverse side effects were rash/eczema and the most common side effects were anxiety, fever, and a mild leukopenia also a severe leukopenia. In addition, the side effects were less common when compared to other immune-based chemotherapy. The most common side effects in this study are not related to ipilimumab so probably would not be seen in other patients with different cancer types." - Anonymous Online Contributor